GeneCentric Therapeutics, Inc.

GeneCentric has launched its EXpressCT?? liquid biopsy platform that allows the value of tissue RNA expression and epigenomics to be realized in liquid biopsy. Until recently, liquid biopsy has not been available to infer gene expression, which can yield greater understanding of tumor biology and support the development of critical diagnostics. EXpressCT adapts RNA-based gene expression signatures to cfDNA liquid biopsy samples to provide deeper insight beyond DNA mutations. Learn more at https://bit.ly/3YqDXG9 #biotechnology #pharmaceuticals #oncology #cancer

Results from the GARNER study have just been published in Clinical Cancer Research. The GARNER study is the largest high-risk non-muscle invasive bladder cancer patient cohort ever assembled with both clinical and genomic detail. Recognizing that DNA alterations may not fully identify all patients who could potentially benefit from FGFR-targeted therapy, the study utilized GeneCentric’s RNA-based FGFR Predictive Response Signature (FGFR-PRS), which identified over twice as many patients with an activated FGFR pathway compared to patients with FGFR DNA alteration biomarkers. Read more at https://bit.ly/3BoqqqL #oncology #precisionmedicine #biotechnology #pharmaceuticals #RNAseq

We’re pleased to announce that our PurIST test has received a proprietary laboratory analysis (PLA) code from the American Medical Association. The PurIST PLA code is the first CPT code created for algorithm-based analysis of previously sequenced RNA data from a laboratory developed test and is a meaningful step toward reimbursement for AI-enabled algorithms. ? PurIST is commercially available under a collaboration agreement with Tempus AI. Together, we’re excited to drive the science and implement this test to benefit patients with #pancreaticcancer. ? Details at https://bit.ly/3SmuHQS. ? #oncology #precisionmedicine #biotechnology #pharmaceuticals #RNAseq

We’re counting down the days until #ASCO24 begins! GeneCentric will have a poster presentation that includes new clinical validation results for a novel signature identifying patients with head and neck squamous cell carcinoma (HNSCC) who may benefit from treatment beyond typical surgical resection. We’ll also present updated findings from our development of a novel RNA-based immune checkpoint inhibition predictive response signature that optimizes the selection of patients with a primary diagnosis of urothelial cancer who are potential candidates for anti-PD-(L)1 inhibition treatment. Details at https://bit.ly/4bnESvX American Society of Clinical Oncology (ASCO) The University of Tennessee Health Science Center University of Pittsburgh School of Medicine #oncology #biotechnology #pharmaceuticals #RNAseq

Did you know that bladder cancer is the 6th most common type of cancer in the U.S., and over 80,000 people will be diagnosed this year? While there has been significant progress in developing new treatments, oncologists need better predictive biomarkers and tests that can inform the optimal treatment for individual patients. We’re advancing a multi-gene RNA expression test to guide the use of FGFR-targeted and other therapies to personalize bladder cancer treatment, so patients may achieve greater clinical benefit. Learn more about our FGFR-PRS test at https://bit.ly/3wms7Ta. #oncology #precisionmedicine #biotechnology #pharmaceuticals #RNAseq

If you missed us at the American Association for Cancer Research 2024 conference, we presented compelling data demonstrating how our PurIST diagnostic test may aid in optimal treatment selection for patients with advanced pancreatic ductal adenocarcinoma. ? We also shared information about our new MSS predictive response signature for colorectal cancer as a potential tool to select patients with MSS tumors who may benefit from ICI-containing treatment regimens. ? View the posters at https://bit.ly/48T1x25. ? #AACR24 #precisionmedicine #oncology #biotechnology Joel Eisner

We’re looking forward to presenting at the American Association for Cancer Research Annual Meeting in San Diego this upcoming week. Join us for two poster presentations featuring data on our PurIST diagnostic test for pancreatic cancer and new MSS predictive response signature for colorectal cancer. Details at https://bit.ly/3TEesP5 #AACR24 #precisionmedicine #oncology #biotechnology

We’ll be at the American Association for Cancer Research Annual Meeting next week in San Diego. Please contact Brian Kelly or [email protected] to meet with our team and learn more about our novel RNA-based diagnostics for oncology. #AACR24 #precisionmedicine #biotechnology #pharmaceuticals

Heading to Precision Med TRI-CON next week in San Diego? Please reach out to Brian Kelly or [email protected] to meet with our team and learn more about our novel RNA-based diagnostics for oncology. #TRICON #precisionmedicine #biotechnology #pharmaceuticals